These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

424 related articles for article (PubMed ID: 14569743)

  • 1. Allogeneic haemopoietic stem cell transplantation using non-myeloablative conditioning--a local experience.
    Leong CF; Cheong SK; Fadilah SA; Ainoon O; Hamidah NH
    Med J Malaysia; 2003 Jun; 58(2):229-35. PubMed ID: 14569743
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Non-myeloablative stem cell transplant].
    Shoji N; Mineishi S
    Gan To Kagaku Ryoho; 2000 Jun; 27(6):795-800. PubMed ID: 10897204
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The graft-versus-leukemia effect of nonmyeloablative stem cell allografts may not be sufficient to cure chronic myelogenous leukemia.
    Sloand E; Childs RW; Solomon S; Greene A; Young NS; Barrett AJ
    Bone Marrow Transplant; 2003 Nov; 32(9):897-901. PubMed ID: 14561990
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Allogeneic blood stem cell transplantation in chronic myeloid leukaemia-chronic phase following conditioning with busulphan and cyclophosphamide: a follow up report.
    Saikia TK; Parikh PM; Tawde S; Amare-Kadam PS; Rajadhyaksha S; Chhaya S
    Natl Med J India; 2004; 17(2):71-3. PubMed ID: 15141598
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Allogeneic hematopoietic transplantation with stem cells extracted from peripheral blood].
    Kusminsky G; Foncuberta MC; Aversa L; Drelichman G; Freigeiro D; Burgos R; Irrazabal C; Gonzalez G; Dictar M; Niborski R; Kohan A; Sanchez Avalos JC
    Medicina (B Aires); 2000; 60(2):179-87. PubMed ID: 10962806
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of a reduced-intensity conditioning regimen for allogeneic transplantation in patients with chronic myeloid leukemia.
    Das M; Saikia TK; Advani SH; Parikh PM; Tawde S
    Bone Marrow Transplant; 2003 Jul; 32(2):125-9. PubMed ID: 12838275
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Non-myeloablative allogeneic stem cell transplantation].
    Dalgaard J; Fløisand Y; Stenersen M; Egeland T; Brinch L
    Tidsskr Nor Laegeforen; 2007 Mar; 127(6):721-4. PubMed ID: 17363982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disease- or therapy-related bone marrow damage cannot be overcome by changes in stem cell source or dose in allogeneic transplantation.
    Novotny JR; Rosenthal C; Elmaagacli AH; Dürig J; Beelen DW; Dührsen U
    Eur J Haematol; 2004 Jul; 73(1):1-9. PubMed ID: 15182331
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical outcomes and direct hospital costs of reduced-intensity allogeneic transplantation in chronic myeloid leukemia.
    Krejci M; Mayer J; Doubek M; Brychtova Y; Pospisil Z; Racil Z; Dvorakova D; Lengerova M; Horky O; Koristek Z; Dolezal T; Vorlicek J
    Bone Marrow Transplant; 2006 Oct; 38(7):483-91. PubMed ID: 16980996
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Allogeneic hematopoietic cell transplantation without myeloablative conditioning for patients with advanced hematologic malignancies.
    Gürman G; Arat M; Ilhan O; Konuk N; Beksaç M; Celebi H; Ozcan M; Arslan O; Ustün C; Akan H; Uysal A; Koç H
    Cytotherapy; 2001; 3(4):253-60. PubMed ID: 12171713
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
    Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
    Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Allogeneic hematopoietic stem cell transplantation in patients with chronic myeloid leukemia in the Czech Republic--a retrospective analysis of results in years 1988-2005].
    Faber E; Koza V; Vítek A; Mayer J; Sedlácek P; Zák P; Zapletalová J; Benesová K; Krejcová H; Steinerová K; Maresová I; Cetkovský P
    Vnitr Lek; 2006 Dec; 52(12):1172-80. PubMed ID: 17299910
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A prospective multicenter trial of peripheral blood stem cell sibling allografts for acute myeloid leukemia in first complete remission using fludarabine-cyclophosphamide reduced intensity conditioning.
    Grigg AP; Gibson J; Bardy PG; Reynolds J; Shuttleworth P; Koelmeyer RL; Szer J; Roberts AW; To LB; Kennedy G; Bradstock KF
    Biol Blood Marrow Transplant; 2007 May; 13(5):560-7. PubMed ID: 17448915
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Indications, technique and risks in bone marrow transplantation in adulthood].
    Heyll A; Söhngen D; Minning H; Meckenstock G; Aul C; Schneider W
    Praxis (Bern 1994); 1996 Mar; 85(12):378-86. PubMed ID: 8643901
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term follow-up of allogeneic hematopoietic stem cell transplantation for de novo acute myelogenous leukemia with a conditioning regimen of total body irradiation and granulocyte colony-stimulating factor-combined high-dose cytarabine.
    Mori T; Aisa Y; Watanabe R; Yamazaki R; Kato J; Shimizu T; Shigematsu N; Kubo A; Yajima T; Hibi T; Ikeda Y; Okamoto S
    Biol Blood Marrow Transplant; 2008 Jun; 14(6):651-7. PubMed ID: 18489990
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Successful engraftment of allogeneic peripheral blood stem cell transplant after nonmyeloablative preparative regimen with cytarabine and cyclophosphamide: report of 2 cases.
    Fujii N; Maeda Y; Takenaka K; Shinagawa K; Imai T; Kozuka T; Ikeda K; Sunami K; Hiramatsu Y; Ishimaru F; Niiya K; Harada M
    Int J Hematol; 2000 Dec; 72(4):499-503. PubMed ID: 11197220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Allogeneic stem cell transplantation for adults with myelodysplastic syndromes: importance of pretransplant disease burden.
    Warlick ED; Cioc A; Defor T; Dolan M; Weisdorf D
    Biol Blood Marrow Transplant; 2009 Jan; 15(1):30-8. PubMed ID: 19135940
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effects and prognostic factors of HLA-matched sibling donor allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia].
    Tong XZ; Li J; Tan EX; Zhang GC; Wu XY; Peng AH; Zheng D; Zou WY; Hong WD; Luo SK
    Zhonghua Zhong Liu Za Zhi; 2006 Jul; 28(7):545-8. PubMed ID: 17147125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential intensified conditioning and tapering of prophylactic immunosuppressants for graft-versus-host disease in allogeneic hematopoietic stem cell transplantation for refractory leukemia.
    Liu QF; Fan ZP; Zhang Y; Jiang ZJ; Wang CY; Xu D; Sun J; Xiao Y; Tan H
    Biol Blood Marrow Transplant; 2009 Nov; 15(11):1376-85. PubMed ID: 19822296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.